Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axelar has started a Phase I/II clinical trial on cancer patients with its new anticancer drug AXL1717, an insulin-like growth factor-1 receptor inhibitor.
Subscribe to our email newsletter
The Phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anticancer effects will be documented whenever possible and the study will be conducted in Sweden.
The preclinical research conducted on AXL1717 demonstrated favorable characteristics in potency, tolerability and pharmacokinetic properties, supporting the exploration of oral dosing in clinical trials.
Johan Harmenberg, CEO of Axelar, said: “Since there exists a significant unmet need for new and effective treatments of cancer, we are extremely pleased that this project has now entered clinical trials. Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy is a new and exciting treatment alternative.”